DSGN — Design Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $213.55m
- -$68.25m
- 38
- 39
- 63
- 44
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 0.077 | 36.1 | 384 | 330 | 282 |
Net Total Receivables | — | — | — | — | 1.43 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.09 | 36.2 | 385 | 335 | 285 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0 | 0.071 | 5.12 | 5.56 | 4.63 |
Other Long Term Assets | |||||
Total Assets | 0.09 | 36.5 | 391 | 341 | 290 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.73 | 2.33 | 5.28 | 10.8 | 9.62 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.73 | 2.48 | 8.43 | 13.8 | 12 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -3.64 | 34 | 382 | 327 | 278 |
Total Liabilities & Shareholders' Equity | 0.09 | 36.5 | 391 | 341 | 290 |
Total Common Shares Outstanding |